Neuraminidase inhibitors: the story behind the Cochrane review
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the story
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
British Medical Association
2009
|
| Online Access: | http://hdl.handle.net/1721.1/50240 |